Oxurion Receives Transparency Notification from Negma Group

Leuven, BELGIUM, Boston, MA, US – March 9, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on March 6, 2023 from Negma Group Ltd. indicating that as of March 1, 2023, it held 15,886,965 shares of the then outstanding 584,702,740 shares, and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV	<u>US</u>
Tom Graney	Conway Communications
Chief Executive Officer	Mary T. Conway
Tel: +32 16 75 13 10	mtconway@conwaycommsir.com
" tom.graney@oxurion.com	
	ICR Westwicke
Michael Dillen	Christopher Brinzey
Chief Business Officer	Tel: +1 617 835 9304
Tel: +32 16 75 13 10	Chris.Brinzey@westwicke.com
michael.dillen@oxurion.com	

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I			
1) Status of the notification				
Final				
2) Issuer				
Name OXURION 0881-620-924				
3) Reason for the notification				
Acquisition or disposal of voting				
Downward crossing of the lowest	uresnoia +			
<u>4) Notification by</u>				
A parent undertaking or a control	+			
5) Persons subject to the notification requirement				
Name	Address (for legal entities)			
Elaf Gassam				
Negma Group Investment Ltd.	Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai (United Arab Emirates)			
Negma Group Ltd.	Craigmuir chambers, Road Town, Tortola, VG 1110 (Brilish Virgin Islands) +			
3) Persons that dispose of voting rights (only to be filled	in if art. 7 of the Law applies)			
Name	Address (for legal entities)			
	+			
Please continue entering the information in part # concerning the persons referred to in Sections 5 and 6 Part II				
7) Date on which the threshold is crossed				
01/03/2023 (DD/MM/YYYY)				
3) Threshold that is crossed (in %)				
3				
🗊 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10				

9) Denominator



10) Notified details

A) Voting rights	Previous notification	After the transaction				
	# of voting rights	# of voti	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Elaf Gassam	0	0		0.00%		
Negma Group Investment Ltd.	0	0		0.00%		
Negma Group Ltd.	18,983,606	15,886,965		2.72%		
Subtotal	18,983,606	15,888,965		2.72%		

-
-
-
+

TOTAL	15,886,965		2.72%	
Start with "groups" of holders. Add subtotals with For groups, start with the ultimate controlling natur The totals, subtotals and % will be updated once yo	al person or legal en	ntity.	are "alone".	

т

т

B) Equivalent financial instruments	After the transaction]		
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement	
							+
	TOTAL						
The totals will be updated once you have clicked on <calculate></calculate>							
TOTAL (A & B) # of voting rights % of voting rights							
			CALCULATE	15,886,965	2.72%	ſ	

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable



12) In case of proxy voting for only one GM

				(DD/MM/YYYY)
Holder	will cease to hold / will hold again	0	voting rights as of	

13) Additional information

Done at Dubai, United Arab Emirates	
On 06/03/2023	(DD/MM/YYYY)
Name & capacity Elaf Gassam, Director	Signature